AI Article Synopsis
- A study involving 19 patients with acute pancreatitis compared high-dose octreotide treatment (9 patients) to a control group that received standard care (10 patients).
- The octreotide group showed a significant reduction in the need for pain relief and developed fewer poor prognostic indicators after 48 hours, such as drops in hematocrit and serum albumin levels.
- Overall, high-dose octreotide appeared to improve various measures of disease severity, suggesting it may help reduce the severity of acute pancreatitis.
Article Abstract
Nineteen consecutive patients with acute pancreatitis were sequentially allocated to treatment with high-dose octreotide (N = 9) or to act as controls (N = 10). All other aspects of treatment were similar and were according to a strict treatment protocol. There was no significant difference between the two groups on admission with regard to recognized criteria of poor prognosis. The octreotide-treated group required significantly less analgesia and after 48 hr developed significantly fewer poor prognostic indicators, including falls in hematocrit of > 10%, in serum albumin to < 32 g/liter, and in serum calcium to < 2.00 mmol/liter. Falls in arterial PO2 to < 10 kPa, in serum albumin of > 20%, and in hemoglobin of > 2 g/dl were also significantly less frequent. There was a trend towards improvement in the octreotide-treated group in every other physiological and radiological indicator of disease severity. High-dose octreotide may reduce the severity of acute pancreatitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01316794 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Somatostatin analogs (SSAs) binding to and activating somatostatin receptors (SSTRs) have been extensively used for the treatment of neuroendocrine tumors (NETs). The currently approved synthetic SSAs have high affinity for SSTR2 (octreotide/lanreotide), or for SSTR2 and SSTR5 (pasireotide). These agents have shown symptoms control and antiproliferative effects in subsets of NET patients and this was associated to the expression of the targeted SSTRs.
View Article and Find Full Text PDFRefractory hypoglycemia is sensitive to octreotide therapy: is it triggered by sorafenib or hepatocellular carcinoma?
Anticancer Drugs
February 2025
Department of Medical Oncology.
Hypoglycemia is a medical emergency with a multitude of potential causes. Paraneoplastic hypoglycemia represents a rare cause of this condition. Hepatocellular carcinoma (HCC) can result in paraneoplastic hypoglycemia through extensive tumor infiltration and the presence of insulin-like growth factor 2 precursors.
View Article and Find Full Text PDF[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet
June 2024
Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.
Article Synopsis
- There are no established first-line treatments for higher grade gastroenteropancreatic neuroendocrine tumors (NETs), prompting a study on the effectiveness of Lu-DOTA-TATE (Lu-Dotatate) as a potential option.
- The NETTER-2 trial was a phase 3 study that randomized patients with advanced NETs to receive either Lu-Dotatate plus octreotide or high-dose octreotide alone, focusing on progression-free survival as the main outcome.
- Results showed that patients receiving Lu-Dotatate had a significantly longer median progression-free survival of 22.8 months compared to 8.5 months for those on high-dose octreotide, indicating Lu-Dotatate may
Lutetium [Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.
Eur J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, IRCCS-Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Purpose: Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [Lu]Lu-DOTA-TATE treatment in Italy.
View Article and Find Full Text PDFHypertensive Crisis in a Patient With a Functioning Mesenteric Paraganglioma: Dramatic Response to Octreotide Treatment.
AACE Clin Case Rep
May 2023
Department of Endocrinology, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), Muscat, Sultanate of Oman.
Background/objective: To report a dramatic and immediate clinical and biochemical response during treatment with octreotide in a patient with a functioning mesenteric paraganglioma (PGL).
Case Report: A 44-year-old woman was admitted with a severe hypertensive crisis and a blood pressure reaching 260/150 mm Hg. She was 2 months postpartum and had been previously diagnosed with pre-eclampsia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!